These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19404957)

  • 21. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Tak PP; Mease PJ; Genovese MC; Kremer J; Haraoui B; Tanaka Y; Bingham CO; Ashrafzadeh A; Travers H; Safa-Leathers S; Kumar S; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):360-70. PubMed ID: 22389919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.
    Alten RE; Zerbini C; Jeka S; Irazoque F; Khatib F; Emery P; Bertasso A; Rabbia M; Caulfield JP
    Ann Rheum Dis; 2010 Feb; 69(2):364-7. PubMed ID: 19357113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
    Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
    Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
    Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
    Kremer JM; Bloom BJ; Breedveld FC; Coombs JH; Fletcher MP; Gruben D; Krishnaswami S; Burgos-Vargas R; Wilkinson B; Zerbini CA; Zwillich SH
    Arthritis Rheum; 2009 Jul; 60(7):1895-905. PubMed ID: 19565475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
    Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J
    Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.